Hospital for Sick Children
The RANK-RANKL axis in B-ALL
Nearly 90% of children with B cell leukemia (B-ALL) are cured. However, many survivors have late effects of the disease including secondary cancers and bone fractures. Cure rates for children who relapse are much poorer due to chemotherapy resistance. How can we protect childhood survivors from late effects of leukemia, and how do leukemic cells gain resistance to therapy? Our project, a collaboration between cancer biologist and a pediatric bone physician, examines how B-ALL damages bone and how the bone protects B-ALL cells from therapy.